Prospects for Immunotherapy in HPV associated Cancer


Educational Session (ES)

Wednesday, June 15, 10.30 – 12.15

Chair: Peter Stern


Four integrated lectures will introduce and explain the importance of immune surveillance in HPV infection and the cutting edge research driving the use of so called checkpoint inhibitors or adoptive cellular transfer or vaccine therapeutic approaches which are beginning to impact on the treatment of different types of cancer. The goal is to provide a session which educates the audience about approaches which are likely to lead to a paradigm shift in the way we approach the therapy of HPV associated disease.
 

1) Understanding immune surveillance in cancer

Professor Peter L Stern

Institute of Cancer Sciences
University of Manchester
UK

2) The importance of inflammatory immune responses in HPV-induced carcinogenesis

Dr. Sigrun Smola

Institut für Virologie
Universitätsklinikum des Saarlandes
Homburg/Saar
Germany

3) Exploiting cell mediated Immunity for cancer therapy

Dr David Gilham

Clinical and Experimental Immunotherapy Group
Institute of Cancer Sciences
Manchester Cancer Research Centre
University of Manchester
UK
 

4) Progress in therapeutic cancer vaccination

Cornelia L. Trimble, M.D.

Gyn/Ob, Oncology, and Pathology
Johns Hopkins Hospital
Baltimore
USA

 

 

 

 

About EUROGIN

EUROGIN (EUropean Research Organisation on Genital Infection and Neoplasia) brings together clinicians and scientists whose work is related to genital infections and neoplasia.

Newsletter